NCT02645149 2026-02-27
Match Mel
Melanoma Institute Australia
Phase 2 Completed
Clinical Trials
6 trialsNCT04594187 2026-02-17
MelPORT
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07407166 2026-02-17
Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers
Institute of Oncology Ljubljana
Phase NA Recruiting
NCT05863052 2026-02-10
Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population
University of Oklahoma
Active not recruiting
NCT06146920 2025-11-18
Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation
Massachusetts General Hospital
Phase NA Active not recruiting
NCT06624644 2025-09-10
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Linnaeus Therapeutics, Inc.
Phase 2/3 Recruiting